Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Cash & Equivalents (2018 - 2026)

TransMedics has reported Cash & Equivalents over the past 8 years, most recently at $488.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 45.08% year-over-year to $488.4 million; the TTM value through Dec 2025 reached $488.4 million, up 45.08%, while the annual FY2025 figure was $488.4 million, 45.08% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $488.4 million at TransMedics, up from $466.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $488.4 million in Q4 2025 and troughed at $17.9 million in Q1 2022.
  • A 5-year average of $245.6 million and a median of $320.1 million in 2024 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: tumbled 50.51% in 2021 and later soared 808.92% in 2022.
  • Year by year, Cash & Equivalents stood at $25.6 million in 2021, then skyrocketed by 686.48% to $201.2 million in 2022, then skyrocketed by 96.25% to $394.8 million in 2023, then decreased by 14.73% to $336.6 million in 2024, then soared by 45.08% to $488.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for TMDX at $488.4 million in Q4 2025, $466.2 million in Q3 2025, and $400.6 million in Q2 2025.